Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
Latest Ratings for RARE Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 JP Morgan Upgrades Neutral Overweight Feb 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for RARE View the Latest Analyst Ratings read more ​ ​Latest Ratings for RARE DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022JP MorganUpgradesNeutralOverweight Feb 2022Morgan